Eli Lilly Receives FDA Approval for Crohn’s Disease Treatment
Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s ...
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® ...
Healio23h
IBD drug market rattles as Lilly’s Omvoh nabs FDA approval for second IL-23p19 in Crohn’s
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...
Clinical Trials Expand Patients' Treatment Options
For health conditions with no cure, effective treatments are the next best option. However, in order to make medical ...
WISH-TV on MSN14h
FDA approves Lilly's Omvoh for Crohn's disease
Indianapolis-based Lilly announced Thursday that the U.S. Food and Drug Administration has approved Omvoh for the treatment ...
pharmaphorum1d
Lilly nets a second FDA okay for Omvoh, in Crohn's disease
Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...
Managed Healthcare Executive18h
FDA Approves Lilly’s Omvoh for Crohn's Disease, Second Indication
More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the ...
Nature23h
Certolizumab pegol
In April 2008, certolizumab pegol (Cimzia; UCB), a tumour-necrosis factor blocker, was approved by the US FDA for the treatment of adult patients with moderate-to-severe Crohn's disease who have ...
FiercePharma1d
JPM25: Takeda spotlights 6 pipeline assets that could pull down up to $20B in collective peak sales
Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...
PharmiWeb4d
AbbVie’s SKYRIZI® (risankizumab) Accepted by the S…
Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative ColitisPRESS RELEASE – For UK consumer health, medical and trade media onlyRisankizumab will be ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
pharmaphorum3d
Abivax sets its course on colitis and Crohn’s
French biotech moves on with the late stage drug development, after publishing impressive clinical trial results of ABX464 for treatment of colitis and hinting its potential in Crohn’s disease.